<DOC>
	<DOC>NCT02536339</DOC>
	<brief_summary>This study will examine the safety and efficacy of pertuzumab in combination with high-dose trastuzumab in adult participants with HER2-positive MBC with CNS metastases and disease progression in the brain following radiotherapy.</brief_summary>
	<brief_title>Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adults at least 18 years of age Pathologically confirmed HER2positive MBC Progression of or new brain metastases after completion of wholebrain radiotherapy or stereotactic radiosurgery Completion of wholebrain radiotherapy or stereotactic radiosurgery more than 60 days prior to enrollment Stable systemic disease Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Left ventricular ejection fraction (LVEF) at least 50% Adequate hematologic, renal, and hepatic function Life expectancy more than 12 weeks Progression of systemic disease at Screening Leptomeningeal disease History of intolerance or hypersensitivity to study drug Use of certain investigational therapies within 21 days prior to enrollment Current anthracycline use Unwillingness to discontinue adotrastuzumab emtansine or lapatinib use Active infection Pregnant or lactating women Significant history or risk of cardiac disease Symptomatic intrinsic lung disease or lung involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>